Luketich J D, Burt M E
Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA.
Ann Thorac Surg. 1996 Dec;62(6):1614-6. doi: 10.1016/s0003-4975(96)00611-x.
Metastatic non-small cell lung cancer (NSCLC) carries a dismal prognosis, which is minimally affected by chemotherapy. Solitary brain metastases from NSCLC have been resected with 5-year survivals of 10% to 30%. The objective of this study was to determine if resection of isolated adrenal metastases improves survival.
Isolated adrenal metastases were found in 14 patients with NSCLC. Eight patients had resection after cis-platinum-based chemotherapy, and 6 received chemotherapy alone.
Median survival in the surgical group was significantly greater than that in the chemotherapy group (31 versus 8.5 months; p = 0.03). All patients in the chemotherapy group were dead by 22 months. Three-year actuarial survival in the surgical group was 38%. No difference in locoregional stage, size of adrenal metastases, patient age, or performance status was present between the two groups.
Long-term disease-free survival is possible after resection of isolated adrenal metastases from NSCLC. Resection of isolated adrenal metastases should be considered if the primary NSCLC is resectable.
转移性非小细胞肺癌(NSCLC)预后不佳,化疗对其影响甚微。NSCLC的孤立性脑转移瘤切除术后5年生存率为10%至30%。本研究的目的是确定切除孤立性肾上腺转移瘤是否能提高生存率。
14例NSCLC患者发现有孤立性肾上腺转移瘤。8例患者在接受铂类化疗后进行了切除,6例仅接受化疗。
手术组的中位生存期显著长于化疗组(31个月对8.5个月;p = 0.03)。化疗组所有患者在22个月时均死亡。手术组的3年精算生存率为38%。两组在局部区域分期、肾上腺转移瘤大小、患者年龄或体能状态方面无差异。
切除NSCLC的孤立性肾上腺转移瘤后可能实现长期无病生存。如果原发性NSCLC可切除,则应考虑切除孤立性肾上腺转移瘤。